Offer - Urjas Oil for just ₹ 1 X
Ceflin S 500 /250 Injection is a prescription drug, available for use as Injection. Secondary and off-label uses of Ceflin S 500 /250 Injection have also been mentioned below.
The correct dosage of Ceflin S 500 /250 Injection depends on the patient's age, gender, and medical history. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Detailed information has been provided in the dosage section.
Some other side effects of Ceflin S 500 /250 Injection have been listed ahead. Normally, these side effects of Ceflin S 500 /250 Injection are not long lasting and go away when the treatment is finished. If, however, they worsen or do not go away, please speak with your physician.
In addition, Ceflin S 500 /250 Injection's effect is Safe during pregnancy and Safe for lactating mothers. Warnings related to Ceflin S 500 /250 Injection's effects on the liver, heart and kidney, if any, have been listed below.
Ceflin S 500 /250 Injection can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Ceflin S 500 /250 Injection in conditions like Kidney Disease, Kidney Disease, Jaundice. Other contraindications of Ceflin S 500 /250 Injection have been discussed in the sections ahead.
Additionally, Ceflin S 500 /250 Injection may also adversely react with other medicines. See below for a complete list.
In addition to these precautions, you may also note that Ceflin S 500 /250 Injection is not safe while driving, and is is not addictive in nature.
Ceflin S 500 /250 Injection is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Ceflin S 500 /250 Injection safe for pregnant women?
Ceflin S is safe to take during pregnancy.
Is the use of Ceflin S 500 /250 Injection safe during breastfeeding?
Ceflin S does not show any side effects in breastfeeding women.
What is the effect of Ceflin S 500 /250 Injection on the Kidneys?
Ceflin S has very mild side effects on the kidneys.
What is the effect of Ceflin S 500 /250 Injection on the Liver?
Ceflin S is not harmful for the liver.
What is the effect of Ceflin S 500 /250 Injection on the Heart?
Ceflin S is completely safe for the heart.
If you are suffering from any of the following diseases, you should not take Ceflin S 500 /250 Injection unless your doctor advises you to do so -
Is this Ceflin S 500 /250 Injection habit forming or addictive?
Forming a habit of Ceflin S 500 /250 Injection has not been reported.
Interaction between Food and Ceflin S 500 /250 Injection
Some foods when eaten with Ceflin S 500 /250 Injection can alter the onset of actions. Discuss this with your doctor.
Interaction between Alcohol and Ceflin S 500 /250 Injection
No research has been done on this till date. Therefore, it is not known what the effect of taking Ceflin S 500 /250 Injection with alcohol will be.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; FORTAZ® (ceftazidime)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-312
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; UNASYN® (ampicillin sodium/sulbactam sodium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 725
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 160-162